Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 2, 2014, Pages 341-350

  Gill, Kathryn M ^a   Cook, James M ^b   Poe, Michael M ^b   Grace, Anthony A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

dopamine supersensitivity; GABA receptor positive allosteric modulator; haloperidol; schizophrenia; ventral tegmental area; withdrawal

Indexed keywords

AMPHETAMINE; APOMORPHINE; HALOPERIDOL; METHYLAZOXYMETHANOL ACETATE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; DIAZEPAM; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABRA5 PROTEIN, RAT; IMIDAZOLE DERIVATIVE; NEUROLEPTIC AGENT; SH-053-2'F-R-CH3; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGICAL PROCEDURES; FEMALE; HISTOLOGY; LOCOMOTION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SUPERSENSITIVITY; TREATMENT RESPONSE; VENTRAL TEGMENTUM; ALLOSTERISM; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; DRUG INTERACTION; HIPPOCAMPUS; MALE; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; WITHDRAWAL SYNDROME;

ALLOSTERIC REGULATION; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DIAZEPAM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; DRUG INTERACTIONS; FEMALE; GABA AGONISTS; HALOPERIDOL; HIPPOCAMPUS; IMIDAZOLES; LOCOMOTION; MALE; METHYLAZOXYMETHANOL ACETATE; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SCHIZOPHRENIA; SODIUM CHLORIDE; SUBSTANCE WITHDRAWAL SYNDROME; VENTRAL TEGMENTAL AREA;

EID: 84895724939     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt236     Document Type: Article

References (61)

1. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654.
2. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717-719.
4. Boyd KN, Mailman RB. Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol. 2012;212:53-86.
5. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68:e04.
6. Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res. 1993;10:267-271.
7. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol- controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
8. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65:1624-1633.
9. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl). 2000;152:174-180.
10. Seeman P, Bzowej NH, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1987;1:5-15.
11. Iyo M, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013;33:398-404.
12. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986.
13. Joyce JN. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse. 2001;40:137-144.
14. Apud JA, Egan MF, Wyatt RJ. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis. Schizophr Res. 2003;63:151-160.
15. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114:3-13.
16. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77:69-77.
17. Cattabeni F, Di Luca M. Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev. 1997;77:199-215.
18. Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael- Titus AT, Didriksen M. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology. 2004;29:2052-2064.
19. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci. 2007;27:11424-11430.
20. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60:253-264.
21. Valenti O, Cifelli P, Gill KM, Grace AA. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci. 2011;31:12330-12338.
22. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology. 2011;36:1903-1911.
23. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumincontaining interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009;29:2344-2354.
24. Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther. 1986;238:1092-1100.
25. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3:1607-1619.
26. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 1983;221:1054-1057.
27. Moore H, Todd CL, Grace AA. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci. 1998;18:5068-5077.
28. Cook JM, Zhou H, Huang S, et al. Strereospecific and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects. 2009; US patent 7,618,958.
29. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology. 2006;31:1356-1361.
30. Valenti O, Gill KM, Grace AA. Different stressors produce excitation or inhibition of mesolimbic dopamine neuron activity: response alteration by stress pre-exposure. Eur J Neurosci. 2012;35:1312-1321.
31. Valenti O, Grace A. Acute and repeated restraint stress induce a pronounced and sustained activation of VTA DA neuron population activity Paper presented at: XXVI Collegium Internationale Neuro-Psychopharmacologicum Congress, July 2008; Munich, Germany.
32. Valenti O, Lodge DJ, Grace AA. Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J Neurosci. 2011;31:4280-4289.
33. Ungless MA, Grace AA. Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci. 2012;35:422-430.
34. Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience. 1983;10:301-315.
35. Paxinos G, Watson C, eds. The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press; 1996.
36. Floresco SB, Todd CL, Grace AA. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci. 2001;21:4915-4922.
37. Bunney BS, Grace AA. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci. 1978;23:1715-1727.
38. Hollerman JR, Abercrombie ED, Grace AA. Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons. Neuroscience. 1992;47:589-601.
39. Carvalho RC, Fukushiro DF, Helfer DC, et al. Long-term haloperidol treatment (but not risperidone) enhances addiction- related behaviors in mice: role of dopamine D2 receptors. Addict Biol. 2009;14:283-293.
40. Komossa K, Rummel-Kluge C, Hunger H, et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006628.
41. Komossa K, Rummel-Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624.
42. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006625.
43. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005;2:CD001359.
44. Heldt SA, Ressler KJ. Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization. Neuroscience. 2007;150:370-385.
45. Hutcheon B, Fritschy JM, Poulter MO. Organization of GABA receptor alpha-subunit clustering in the developing rat neocortex and hippocampus. Eur J Neurosci. 2004;19:2475-2487.
46. June HL, Harvey SC, Foster KL, et al. GABA(A) receptors containing (alpha)5 subunits in the CA1 and CA3 hippocampal fields regulate ethanol-motivated behaviors: an extended ethanol reward circuitry. J Neurosci. 2001;21:2166-2177.
47. Lingford-Hughes A, Hume SP, Feeney A, et al. Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab. 2002;22:878-889.
48. Papatheodoropoulos C, Koniaris E. α5GABAA receptors regulate hippocampal sharp wave-ripple activity in vitro. Neuropharmacology. 2011;60:662-673.
49. Ramos B, Lopez-Tellez JF, Vela J, et al. Expression of alpha 5 GABAA receptor subunit in developing rat hippocampus. Brain Res Dev Brain Res. 2004;151:87-98.
50. Sur C, Fresu L, Howell O, McKernan RM, Atack Jr. Autoradiographic localization of alpha5 subunit-containing GABAA receptors in rat brain. Brain Res. 1999;822:265-270.
51. Towers SK, Gloveli T, Traub RD, et al. Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. J Physiol. 2004;559:721-728.
52. Laruelle M, Jaskiw GE, Lipska BK, et al. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res. 1992;575:47-56.
53. Huang N, Ase AR, Hebert C, van Gelder NM, Reader TA. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem Int. 1997;30:277-290.
54. D'Souza U, McGuffin P, Buckland PR. Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA. Neuropharmacology. 1997;36:1689-1696.
55. Xu H, Yang HJ, Rose GM. Chronic haloperidol-induced spatial memory deficits accompany the upregulation of D(1) and D(2) receptors in the caudate putamen of C57BL/6 mouse. Life Sci. 2012;91:322-328.
56. Seeman P, Weinshenker D, Quirion R, et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A. 2005;102:3513-3518.
57. Bedard AM, Maheux J, Levesque D, Samaha AN. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia. Schizophr Bull. 2013;39:692-702.
58. Braszko JJ, Bannon MJ, Bunney BS, Roth RH. Intrastriatal kainic acid: acute effects on electrophysiological and biochemical measures of nigrostriatal dopaminergic activity. J Pharmacol Exp Ther. 1981;216:289-293.
59. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci. 2003;6:968-973.
60. Vasconcelos SM, Nascimento VS, Nogueira CR, et al. Effects of haloperidol on rat behavior and density of dopaminergic D2-like receptors. Behav Processes. 2003;63:45-52.
61. French SJ, Totterdell S. Individual nucleus accumbens-projection neurons receive both basolateral amygdala and ventral subicular afferents in rats. Neuroscience. 2003;119:19-31.